Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0119 • ACR Convergence 2024
Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis
Basant Elnady¹, Ziyad Alakkas², Sultana Abdulaziz³, Hussain Halabi⁴, Ahmed A. G. Ibrahim⁵, Hoda E. Draz⁵, Mohammed Attar⁶, Hassan Daghasi⁷, Abeer Alhalwani⁸, Reman Shaker⁹ and Ghadeer Maher Elsheikh¹⁰, ¹Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, ²King Faisal Medical Complex, Taif, Saudi Arabia, ³King Fahad Hospital, Jeddah, Saudi Arabia, ⁴King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, ⁵Benha University, Benha, Egypt, ⁶al hada armed forces hospital, Taif, Saudi Arabia, ⁷Alhada military hospital, Taif, Saudi Arabia, ⁸East Jeddah hospital, Jeddah, Saudi Arabia, ⁹King Faisal Specialist Hospital and Research centre, Jeddah, Saudi Arabia, ¹⁰Menoufia University, Menoufia, Egypt
Background/Purpose: Antiphospholipid syndrome (APS) is closely linked with Systemic Lupus erythematosus (SLE) and can influence patient outcomes. The interplay between APS and SLE, including the evolution…
Abstract Number: 0182 • ACR Convergence 2024
Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Patricia Nogueira De Sa¹, Stephanie Wirtshafter¹, Abdallah Geara² and Kimberly DeQuattro², ¹University of Pennsylvania, Pennsylvania, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune condition that disproportionally affects individuals from racial and ethnic minority groups with more than 95%…
Abstract Number: 0217 • ACR Convergence 2024
Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
Joy Buie¹, Safoah Agyemang¹ and Joan Merrill², ¹Lupus Foundation of America, Washington, DC, ²Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …
Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Rashmi Dhital¹, Kerri Bertrand², Essi Heinonen³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, CA, ³UC San Diego, La Jolla, CA; Karolinska Institutet, Stockholm, Sweden, San Diego, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…
Abstract Number: 0611 • ACR Convergence 2024
Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
Arthur Mageau¹, Marie-Paule Chauveheid², Chrystelle Francois², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…
Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Anca Askanase¹, Edward Vital², Oliver Meier³, Armando Turchetta⁴, Huiyan (Ashley) Mao⁴, Justine Maller⁵, Jorge A. Ross Terres⁶ and Maria Dall'Era⁷, ¹Columbia University Medical Center, New York, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc,, San Francisco, CA, ⁶Genentech, Inc,, San Francisco, ⁷UCSF, Corte Madera, CA
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos², Jasneet Singh², Ingrid Lazaridou², Markos Kalligeros², Eleftherios Mylonakis³ and Anthony M. Reginato⁴, ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, RI, ³Department of Medicine, Houston Methodist Hospital, Houston, ⁴Brown University, Providence, RI
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 0816 • ACR Convergence 2024
Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
James Ward¹, Mythri Ambatipudi², Zerai Manna³, Michael Smith⁴, Melissa de los Reyes⁵, Adam Schiffenbauer⁶, Saifur Rahman⁷, Kamelia Zerrouki⁵, Fredrick Miller¹, Mariana Kaplan⁸, Jian-Liang Li¹, Kerry Casey⁹, Lisa Rider¹⁰ and Sarfaraz Hasni⁶, ¹National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Harvard Medical School, Boston, MA, ³NIH, Bethesda, MD, ⁴Horizon Therapeutics, Alexandria, VA, ⁵AstraZeneca, Gaithersburg, MD, ⁶NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁷AstraZeneca, Gaithersburg, ⁸NIAMS/NIH, Bethesda, MD, ⁹Regeneron Pharmaceuticals, Terrytown, NY, ¹⁰NIEHS, NIH, Garrett Park, MD
Background/Purpose: Systemic lupus erythematosus (SLE) and dermatomyositis (DM) are hypothesized to be triggered by shared genetic and environmental factors leading to aberrant activation of innate…
Abstract Number: 0997 • ACR Convergence 2024
Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus
Zoe Reed¹, Janis Campbell², Xana Howard¹, Teresa Aberle¹, Bridget Parrish¹, Wade DeJager³, Cristina Arriens¹, Joan Merrill⁴ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) has a complex etiology with genetic predispositions interacting with environmental factors. Extensive environmental exposure information is now publicly available based…
Abstract Number: 1240 • ACR Convergence 2024
Living with Antiphospholipid Antibodies: A Photovoice Exploration
Francesca Cardwell¹, Susan J. Elliott², Paul S. Gibson³, Nancy Soliman⁴, Leslie Skeith⁴, Ann E. Clarke⁵ and Megan Barber⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, ON, Canada, ⁵Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…
Abstract Number: 1278 • ACR Convergence 2024
The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Hunter Hogarth¹, Jida Jaffan¹, Tala El Tal², Oscar Mwizerwa¹, Asha Jeyanathan¹, Ibrahim Mohamed³, Lawrence Ng⁴, Paris Moaf⁵, Joanna Law⁵, Louise Boulard⁶, Ashley Danguecan⁷, Adrienne Davis⁸, Linda Hiraki⁴, Deborah Levy⁴ and Andrea Knight⁹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ²The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁸Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Fatigue is a prevalent and distressing symptom in childhood-onset systemic lupus erythematosus (cSLE), affecting up to 74% of patients with potential for adverse effects…
Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 1509 • ACR Convergence 2024
Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Rosana Quintana¹, Guillermo Pons-Estel², Karen Roberts³, Erika S. Palacios Santillan³, Íñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Pablo Ibañez⁶, Leonel Ariel Berbotto⁷, Maria Constanza Bertolaccini⁸, Marina Laura Micelli⁹, Cecilia Pisoni¹⁰, Vitalina De Souza Barbosa¹¹, Henrique de Ataíde Mariz¹², Francinne Machado Ribeiro¹³, Luciana Parente¹⁴, Emília Sato¹⁵, Milena Mimica Davet¹⁶, Gustavo Aroca Martínez¹⁷, Fabio Bonilla-Abadía¹⁸, Gerardo Quintana López¹⁹, Reyna E. Sánchez Briones²⁰, Mario Pérez Cristóbal²¹, Luis H. Silveira Torre²², Ignacio García De La Torre²³, Ivan Morales Avendaño²⁴, Pablo Gamez-Siller²⁵, Astrid Paats²⁶, Jorge N. Cieza Calderón²⁷, Andy Armando Mendoza Maldonado²⁸, Martin Rebella²⁹, Gonzalo Silveira³⁰, John Fredy Jaramillo³¹, Monica Sanchez³², Urbano Sbarigia³³, Ashley Orillion³⁴, Federico Zazzetti³⁵, Graciela Alarcon³⁶ and Bernardo Pons-Estel³⁷, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ³Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁵Galicia Health Service (SERGAS), Vigo, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Planta, Argentina, ⁷Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ⁸Servicio de Reumatologia - Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina, ⁹Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁰CEMIC, Buenos Aires, Argentina, ¹¹Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹²Universidad Federal de Pernambuco, Recife, Brazil, ¹³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ¹⁶Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ¹⁷Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ²¹Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ²²Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ²³Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ²⁴Hospital Central Dr. Ignacio Morones Prieto, Potosi, Mexico, ²⁵Servicio de Reumatologia del Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²⁶Hospital de Clínicas I, Asunción, Paraguay, ²⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ²⁸Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁹Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ³⁰Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Unidad Nefrologia,Hospital fernandez, CABA, Argentina, ³³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³⁴Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁵Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁶The University of Alabama at Birmingham, Oakland, CA, ³⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of serious infections, which in turn, are associated with morbidity and mortality. The Systemic…
Abstract Number: 1526 • ACR Convergence 2024
Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus
Havell Markus¹, Chachrit Khunsriraksakul¹, Galen Foulke², Laura Carrel¹, Nancy Olsen³ and Dajiang Liu¹, ¹Penn State College of Medicine, Hershey, PA, ²Penn State Health, Hershey, PA, ³Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a severe and heterogeneous autoimmune disease. SLE is often preceded by a stage with milder symptoms and positive antinuclear…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].